H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
H-1PV
combination therapies
oncolytic virus immune therapy
rodent protoparvoviruses
second generation parvovirus treatments
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
18 06 2019
18 06 2019
Historique:
received:
16
05
2019
revised:
13
06
2019
accepted:
14
06
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
25
7
2020
Statut:
epublish
Résumé
The rat protoparvovirus H-1PV is nonpathogenic in humans, replicates preferentially in cancer cells, and has natural oncolytic and oncosuppressive activities. The virus is able to kill cancer cells by activating several cell death pathways. H-1PV-mediated cancer cell death is often immunogenic and triggers anticancer immune responses. The safety and tolerability of H-1PV treatment has been demonstrated in early clinical studies in glioma and pancreatic carcinoma patients. Virus treatment was associated with surrogate signs of efficacy including immune conversion of tumor microenvironment, effective virus distribution into the tumor bed even after systemic administration, and improved patient overall survival compared with historical control. However, monotherapeutic use of the virus was unable to eradicate tumors. Thus, further studies are needed to improve H-1PV's anticancer profile. In this review, we describe H-1PV's anticancer properties and discuss recent efforts to improve the efficacy of H-1PV and, thereby, the clinical outcome of H-1PV-based therapies.
Identifiants
pubmed: 31216641
pii: v11060562
doi: 10.3390/v11060562
pmc: PMC6630270
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Virol. 1999 May;73(5):3877-85
pubmed: 10196282
J Virol. 2001 May;75(9):4394-8
pubmed: 11287588
Dev Cell. 2001 Aug;1(2):291-302
pubmed: 11702787
Cancer Gene Ther. 2001 Dec;8(12):958-65
pubmed: 11781658
Cancer Res. 2002 Sep 15;62(18):5139-43
pubmed: 12234975
J Virol. 2002 Oct;76(20):10307-19
pubmed: 12239307
Cancer Gene Ther. 2003 Jun;10(6):477-80
pubmed: 12768193
Bull N Y Acad Med. 1961 May;37:305-10
pubmed: 13777425
Proc Soc Exp Biol Med. 1965 Jul;119:711-5
pubmed: 14328982
J Gene Med. 2004 Feb;6 Suppl 1:S193-202
pubmed: 14978762
Med Microbiol Immunol. 1992;181(3):153-64
pubmed: 1522825
Blood. 2005 Jan 15;105(2):728-34
pubmed: 15367432
Curr Gene Ther. 2004 Sep;4(3):249-61
pubmed: 15384939
Neoplasia. 2004 Nov-Dec;6(6):725-35
pubmed: 15720798
Hum Gene Ther. 2005 Jun;16(6):765-78
pubmed: 15960607
Hum Gene Ther. 2005 Aug;16(8):996-1005
pubmed: 16076257
J Virol. 2006 Jan;80(2):1015-24
pubmed: 16379002
Nat Rev Cancer. 2006 Jan;6(1):38-51
pubmed: 16397526
Proc Natl Acad Sci U S A. 1960 Sep;46(9):1256-8
pubmed: 16590744
J Virol. 2007 Apr;81(8):4186-98
pubmed: 17287256
Adv Virus Res. 2007;70:183-232
pubmed: 17765706
Int J Cancer. 2008 Jun 15;122(12):2880-4
pubmed: 18360875
Trends Microbiol. 2008 May;16(5):208-14
pubmed: 18406140
PLoS Pathog. 2008 Aug 15;4(8):e1000126
pubmed: 18704167
Clin Cancer Res. 2009 Jan 15;15(2):511-9
pubmed: 19147756
J Virol. 2009 Jun;83(11):5854-63
pubmed: 19321616
Int J Cancer. 2010 Jun 15;126(12):2914-27
pubmed: 19856310
J Virol. 2010 Jan;84(1):516-31
pubmed: 19864388
J Virol. 2010 Feb;84(4):2090-9
pubmed: 19939915
Mol Ther. 2010 Feb;18(2):251-63
pubmed: 20029399
J Biomed Biotechnol. 2010;2010:350748
pubmed: 20224643
Neuro Oncol. 2010 Aug;12(8):804-14
pubmed: 20299703
J Virol. 2010 Jun;84(12):5909-22
pubmed: 20375165
Int J Cancer. 2011 Feb 15;128(4):908-19
pubmed: 20473905
Cancer Gene Ther. 2011 Apr;18(4):240-9
pubmed: 21102423
Cancer Biol Ther. 2010 Dec 15;10(12):1280-9
pubmed: 21124075
Clin Cancer Res. 2011 Aug 15;17(16):5333-42
pubmed: 21715567
Curr Pharm Biotechnol. 2012 Jul;13(9):1817-33
pubmed: 21740354
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
J Virol. 2012 Apr;86(7):3452-65
pubmed: 22258256
J Vis Exp. 2012 Apr 23;(62):null
pubmed: 22546707
J Virol. 2012 Jul;86(14):7554-64
pubmed: 22553326
Clin Cancer Res. 2012 Jul 1;18(13):3516-23
pubmed: 22566376
Cancer Immunol Immunother. 2012 Nov;61(11):2113-23
pubmed: 22576056
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
J Virol. 2012 Oct;86(19):10418-31
pubmed: 22787235
Cancer Res. 2013 Feb 15;73(4):1265-75
pubmed: 23393196
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
J Virol. 2013 May;87(9):5128-40
pubmed: 23449783
Virology. 2013 Jul 20;442(1):20-7
pubmed: 23676303
J Virol. 2013 Oct;87(19):10501-14
pubmed: 23903839
Virology. 2013 Nov;446(1-2):37-48
pubmed: 24074565
EMBO Mol Med. 2013 Oct;5(10):1537-55
pubmed: 24092664
PLoS Pathog. 2013 Oct;9(10):e1003671
pubmed: 24204256
Virology. 2013 Dec;447(1-2):221-32
pubmed: 24210118
Arch Virol. 2014 May;159(5):1239-47
pubmed: 24212889
J Virol. 2014 May;88(9):4932-42
pubmed: 24554651
J Virol. 2014 May;88(10):5263-76
pubmed: 24574398
Ann Oncol. 2014 Aug;25(8):1650-6
pubmed: 24759568
Cancer Immunol Res. 2014 Apr;2(4):295-300
pubmed: 24764576
Front Oncol. 2014 May 01;4:92
pubmed: 24822170
Adv Exp Med Biol. 2014;818:99-124
pubmed: 25001533
Genome Announc. 2014 Jul 31;2(4):null
pubmed: 25081268
Virol J. 2015 Jan 29;12:6
pubmed: 25630937
Comp Med. 2015 Feb;65(1):23-35
pubmed: 25730754
Comp Med. 2015 Feb;65(1):36-45
pubmed: 25730755
PLoS Pathog. 2015 Mar 05;11(3):e1004703
pubmed: 25742010
Curr Opin Virol. 2015 Aug;13:17-24
pubmed: 25841215
Front Bioeng Biotechnol. 2015 Apr 22;3:55
pubmed: 25954743
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Nature. 2015 Oct 29;526(7575):622-3
pubmed: 26511559
Viruses. 2016 Jan 06;8(1):null
pubmed: 26751469
Annu Rev Virol. 2014 Nov;1(1):517-37
pubmed: 26958732
EBioMedicine. 2016 Jul;9:31-36
pubmed: 27407036
Hum Gene Ther. 2017 Mar;28(3):295-306
pubmed: 28042949
Front Oncol. 2017 May 12;7:93
pubmed: 28553616
BMC Cancer. 2017 Aug 29;17(1):576
pubmed: 28851316
Immunol Rev. 2017 Nov;280(1):220-230
pubmed: 29027232
Viruses. 2017 Oct 26;9(11):
pubmed: 29072600
Viruses. 2017 Oct 31;9(11):
pubmed: 29088070
Oncotarget. 2017 May 31;8(60):102617-102639
pubmed: 29254276
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846
pubmed: 29420123
Viruses. 2018 Mar 27;10(4):
pubmed: 29584637
Nat Rev Cancer. 2018 Jul;18(7):419-432
pubmed: 29695749
EBioMedicine. 2018 May;31:17-24
pubmed: 29724655
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
J Cell Physiol. 2019 May;234(5):5700-5721
pubmed: 30378106
Clin Transl Med. 2018 Nov 14;7(1):35
pubmed: 30426287
Viruses. 2019 May 04;11(5):null
pubmed: 31060205
Nature. 1967 Jun 3;214(5092):1036
pubmed: 4964635
Virology. 1968 Jul;35(3):475-8
pubmed: 5662871
Cancer Res. 1982 Jul;42(7):2552-5
pubmed: 6805941
J Virol. 1995 Jul;69(7):4538-43
pubmed: 7769719
J Virol. 1995 Mar;69(3):1652-60
pubmed: 7853501
J Virol. 1996 Mar;70(3):1331-9
pubmed: 8627649
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Virology. 1999 Feb 1;254(1):169-81
pubmed: 9927584